尊龙凯时·(中国)人生就是搏!

Non-invasive Prenatal Screening Version 1.0
Introduction

Non-invasive Prenatal Screening Version 1.0 (NIPSv1.0), is an upgraded product of NIPS. By upgrading and optimizing the analytical workflow of NIPS, NIPSv1.0 increases the screening number of diseases to 18.

NIPS1.0 increases the screening number of diseases to 18 Based on an innovative NIPS-SCCD analytical workflow, NIPSv1.0 adopts a two-channel data analytical model and a three-dimensional filtering system, which can detect 18 fetal chromosomal diseases simultaneously, including trisomy 21, trisomy 18, trisomy 13, and 11 microdeletion or microdeletion syndromes with relatively high incidence.

Advantages

NIPSv1.0 adopts an innovative NIPS-SCCD analytical workflow, which is based on a NTBD background database independently constructed by Annoroad. The NTBD dataset is subgrouped into 9 subsets by their characteristics. Sequencing data for each sample will be mapped to one of the subsets. This process can significantly reduce the interference caused by individual differences, transportation conditions, and experimental processes. Meanwhile, by adopting a multiple-dimensional analytical strategy and bidirectional correction, systematic errors can be reduced and the true status of the chromosomes can be revealed. The two-channel data analytical model is used for independent data analysis and mutual verification of the results. Then, through the assessment of the three-dimensional filtering system, the accuracy of the candidate results can be further guaranteed.

Applicable
  • NIPSv1.0 is appropriate for pregnant women with fully informed consent, particularly those with a singleton or twin pregnancy at 12–22 weeks of gestation.
  • Pregnant women who are at moderate risk of common chromosome aneuploidy through Down's serological screening and ultrasonic imaging examination;
  • Pregnant women with contraindications to invasive prenatal diagnosis (such as threatened abortion, fever, bleeding tendency, and unhealed infection, etc.);
  • Pregnant women who missed the optimal time for serological screening or prenatal diagnosis.
友情链接:百度一下 搜索 360搜索 网站首页
尊龙凯时